Remote Medical writing Jobs · Medical Affairs

• Execute the strategic FMA training plan supporting the therapeutic area Business Unit and new product launch initiatives.
• Develop and refine the GMA new hire FMA learning curriculum for their therapeutic area (i.e., Nephrology/Immunology).
• Lead virtual classrooms, competency assessments & certifications (live and virtual) and serve as a key presenter and co-author of the Peak Performers series.

Otsuka is a global healthcare company committed to developing and commercializing innovative products in neuroscience, nephrology, and digital medicine. The company employs 34,400 people worldwide, including 2,200 in the U.S., and is dedicated to defying limitations for patients and earning recognition as a Great Place to Work.

• Serve as key person between Medical Affairs and cross-functional partners.
• Proactively identify inefficiencies and duplication of effort across Medical Affairs.
• Maintain and continuously optimize Medical Affairs SOPs and policies.

EyePoint is a patient-centric and award-winning ophthalmology company that focuses on science and innovation to offer a lifetime of clearer vision. They specialize in sustained-release treatments for serious retinal diseases and empower curiosity and innovation in a science-based entrepreneurial culture.

• Lead and develop a high-performing MSL team within a region, setting clear expectations for scientific excellence, compliance, and professional growth
• Translate medical strategy into effective field execution, ensuring consistent, high-quality scientific engagement across territories
• Ensure the timely collection, synthesis, and communication of actionable medical insights from the field to inform clinical development, medical strategy, and education planning

Compass Pathways plc is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. They are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of their investigational COMP360 synthetic psilocybin treatment.